Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The same clinical encounter is shown in Additional file 1: Box 2, and illustrates how the provider addresses primary care concerns and establishes priorities during a routine clinical visit.Types of decisions and referrals made during the Clinical EncountersTaking a chemoprevention pill5Having mammography screening4Having a colonoscopy3Taking a vitamin D supplement3Changing diet2Having genetic counseling2Seeing a psychiatrist2Having vaccinations2Seeing a gastroenterologist2Consultation with breast clinic1Having physical therapy1Having a 24-h urine test1Having a blood test to check A1C level1Having a heart stress test1Seeing a nutritionist1Seeing a social worker1Starting an exercise program1Taking a blood pressure medication1Taking a medication for foot infection1Taking alternative medicine1Taking a mood stabilizer1Taking a medication to lower cholesterol1Taking insulin medication1Using an incentive spirometer1Using a sleep apnea machine1Total41

Source: Theme 1: competing demands during clinical encounters. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Multiple reported designs.

Multiple reported designs

More than one design is explicitly reported; examine the supporting methods.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Qualitative analysis of shared decision-making for chemoprevention in the primary care setting: provider-related barriers

Source: Article title.

PCPs included internists, family practitioners, and gynecologists, whereas patients were high-risk women, age 35 to 75 years, who had a 5-year invasive breast cancer risk ≥ 1.67%, according to the Gail model.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Qualitative analysis of shared decision-making for chemoprevention in the primary care setting: provider-related barriers

Multiple reported designs · BMC Medical Informatics and Decision Making · 2022

Original publication title

Qualitative analysis of shared decision-making for chemoprevention in the primary care setting: provider-related barriers

Tarsha Jones; Thomas Silverman; Ashlee Guzman; Julia E. McGuinness; Meghna S. Trivedi; Rita Kukafka; Katherine D. Crew

© The Author(s) 2022

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Critical barriers to SDM about chemoprevention were identified among PCPs. Providers need education and resources through decision support tools to engage in risk communication and SDM with their high-risk patients, and to gain confidence in prescribing chemoprevention in the primary care setting.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Chemoprevention with anti-estrogens, such as tamoxifen, raloxifene or aromatase inhibitors, have been shown to reduce breast cancer risk in randomized controlled trials; however, uptake among women at high-risk for developing breast cancer remains low. The aim of this study is to identify provider-related barriers to shared decision-making (SDM) for chemoprevention in the primary care setting.

Source: Background

Abstract: What methods does the paper describe?

Primary care providers (PCPs) and high-risk women eligible for chemoprevention were enrolled in a pilot study and a randomized clinical trial of web-based decision support tools to increase chemoprevention uptake. PCPs included internists, family practitioners, and gynecologists, whereas patients were high-risk women, age 35 to 75 years, who had a 5-year invasive breast cancer risk ≥ 1.67%, according to the Gail model. Seven clinical encounters of high-risk women and their PCPs who were given access to these decision support tools were included in this study.

Audio-recordings of the clinical encounters were transcribed verbatim and analyzed using grounded theory methodology.

Source: Methods

Abstract: Results

Six primary care providers, of which four were males (mean age 36 [SD 6.5]) and two were females (mean age 39, [SD 11.5]) and seven racially/ethnically diverse high-risk female patients participated in this study. Qualitative analysis revealed three themes: (1) Competing demands during clinical encounters; (2) lack of knowledge among providers about chemoprevention; and (3) limited risk communication during clinical encounters.

Source: Results

Abstract: Conclusions

Critical barriers to SDM about chemoprevention were identified among PCPs. Providers need education and resources through decision support tools to engage in risk communication and SDM with their high-risk patients, and to gain confidence in prescribing chemoprevention in the primary care setting.

Source: Conclusions
Authors’ abstract

Background

Chemoprevention with anti-estrogens, such as tamoxifen, raloxifene or aromatase inhibitors, have been shown to reduce breast cancer risk in randomized controlled trials; however, uptake among women at high-risk for developing breast cancer remains low. The aim of this study is to identify provider-related barriers to shared decision-making (SDM) for chemoprevention in the primary care setting.

Methods

Primary care providers (PCPs) and high-risk women eligible for chemoprevention were enrolled in a pilot study and a randomized clinical trial of web-based decision support tools to increase chemoprevention uptake. PCPs included internists, family practitioners, and gynecologists, whereas patients were high-risk women, age 35 to 75 years, who had a 5-year invasive breast cancer risk ≥ 1.67%, according to the Gail model. Seven clinical encounters of high-risk women and their PCPs who were given access to these decision support tools were included in this study.

Audio-recordings of the clinical encounters were transcribed verbatim and analyzed using grounded theory methodology.

Results

Six primary care providers, of which four were males (mean age 36 [SD 6.5]) and two were females (mean age 39, [SD 11.5]) and seven racially/ethnically diverse high-risk female patients participated in this study. Qualitative analysis revealed three themes: (1) Competing demands during clinical encounters; (2) lack of knowledge among providers about chemoprevention; and (3) limited risk communication during clinical encounters.

Conclusions

Critical barriers to SDM about chemoprevention were identified among PCPs. Providers need education and resources through decision support tools to engage in risk communication and SDM with their high-risk patients, and to gain confidence in prescribing chemoprevention in the primary care setting.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12911-022-01954-y.

Publication and source details

Original title: Qualitative analysis of shared decision-making for chemoprevention in the primary care setting: provider-related barriers

Tarsha Jones; Thomas Silverman; Ashlee Guzman; Julia E. McGuinness; Meghna S. Trivedi; Rita Kukafka; Katherine D. Crew

BMC Medical Informatics and Decision Making · 2022

© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.National Cancer Institute1K01CA241393-01A1ClinicalTrials.gov Identifier: NCT03069742ClinicalTrials.gov Identifier: NCT03069742ClinicalTrials.gov Identifier: NCT03069742ClinicalTrials.gov Identifier: NCT03069742ClinicalTrials.gov Identifier: NCT03069742ClinicalTrials.gov Identifier: NCT03069742Jones Tarsha Silverman Thomas Guzman Ashlee McGuinness Julia E. Trivedi Meghna S. Kukafka Rita Crew Katherine D. http://dx.doi.org/10.13039/100007316Division of Cancer Prevention, National Cancer InstituteR01 CA177995-01A1R01 CA177995-01A1R01 CA177995-01A1R01 CA177995-01A1R01 CA177995-01A1R01 CA177995-01A1R01 CA177995-01A1Jones Tarsha Silverman Thomas Guzman Ashlee McGuinness Julia E. Trivedi Meghna S. Kukafka Rita Crew Katherine D. NCIR01CA177995-05S1R01CA177995-05S1Jones Tarsha Crew Katherine D.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T08:07:10.253680+00:00

DOI: 10.1186/s12911-022-01954-y · PMC9354269